-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ruxolitinib is a pioneering oral Janus kinase 1 and Janus kinase 2 (JAK1/JAK2) inhibitors.
the drug's current symptoms include bone fibrosis, true erythrocytosis (PV), corticosteroid incurable acute graft anti-host disease (GvHD).
the U.S. market, the drug is branded Jakafi and sold by Incyte, and outside the U.S., the drug is named Jakavi and is sold by Novaral.
Currently, Incyte is also developing ruxolitinib emulsions, which are being clinically developed in Phase III: (1) for the treatment of patients with mild to moderate idiopathic dermatitis (TRuE-AD) and (2) for the treatment of adolescent and adult vitiligo (TRuE-V).
Incyte has global rights to develop and commercialize ruxolitinib emulsions.
previously published Phase II study data showed that patients in the ruxolitinib emulsion treatment group had significantly improved their facial vitiligo severity index scores and significantly improved their overall vitiligo skin loss complex compared to the additive control (drug-free cream) group.
february this year, ruxolitinib emulsion treatment for special dermatitis Phase III project was a success.
() Original origin: Novartis announces first data from REACH3 trial show Jakavi? (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD。
